Comparison

Anti-Human CD34 (HB-34a) - Purified No Carrier Protein - 500 µg

Item no. LEIN-C943-500ug
Manufacturer Leinco Technologies
Amount 500 ug
Quantity options 100 ug 25 ug 500 ug
Category
Type Antibody Monoclonal
Applications WB, FC, IF, IHC, ELISA
Clone HB-34a
Specific against other
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Category
Monoclonal Antibodies|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers
Manufacturer - Targets
CD34
Shipping Temperature
2 - 8°C Wet Ice
Storage Conditions
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Product Description
CD34 is a transmembrane phosphoglycoprotein that contains a heavily sialylated extracellular domain, O- and N-linked glycosylation sites, a single transmembrane helix, and a cytoplasmic tail that contains PDZ-domain binding motifs 1. CD34 interacts with L-selectin (CD62L), CrkL 1, and integrin 2 and also exerts a synergistic effect with inflammatory cytokines and chemokines 2. CD34 functions in cell adhesion, regulation of cell differentiation and proliferation, trafficking of hematopoietic stem cells to niches within the bone marrow 1, adult angiogenesis 3, inflammatory cell chemotaxis, and enhancement of the inflammatory response 2. Additionally, CD34 is involved in cell migration, via the recruitment of lymphocytes to specialized high endothelial venules that line the secondary lymphoid organs, as well as T cell homing to these lymphoid organs 4. CD34 is routinely used in clinical settings to identify and isolate hematopoietic stem and progenitor cells for bone marrow transplants to ensure rapid engraftment 1, for example during hematopoietic reconstitution after myeloablative therapy in cancer patients 4. CD34+ autologous stem cells are also used as a novel therapeutic for ischemia with non-obstructive coronary arteries with coronary microvascular dysfunction 3. Clinical trials have investigated the use of CD34+ stem cell therapy in peripheral ischemia, nonischemic cardiomyopathy, myocardial infarction, ischemic stroke, and refractory angina. Additionally, CD34 expression is abnormally high in the intestine of inflammatory bowel disease (IBD) patients and is involved in the occurrence and development of IBD via its interactions with adhesion molecules as well as playing a role in the migration of immune cells to the inflammatory site 2.
Manufacturer - Research Area
Cell Adhesion, Cell Biology, Immunology, Neuroscience, Stem Cell
Concentration
≥1.0 mg/ml
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Antigen Distribution
CD34 is a general marker of progenitor cells. CD34 is expressed on hematopoietic stem and progenitor cells as well as nonhematopoietic cell types including vascular endothelial progenitors, fibrocytes, mesenchymal stromal cells, interstitial cells, epithelial progenitors, muscle satellite cells, corneal keratocytes, vascular endothelial progenitors, mucosal dendritic cells, mast cells, and eosinophils.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Delivery expected until 10/30/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close